The Intercept IQ™ Pipeline
The Intercept IQ™ platform is designed to support the discovery, development, and commercialization of molecular diagnostics across metabolic disease, oncology, neurology, and future disease applications. Each program leverages a shared foundation of liquid biopsy, multi-omic biomarker analysis, artificial intelligence, and precision molecular diagnostics.
Section 01
Unlike traditional diagnostics built around a single biomarker or disease, Intercept IQ is a scalable molecular intelligence platform capable of supporting multiple disease interception programs through a common scientific and technological infrastructure.
Liquid Biopsy
Cell-Free DNA
Epigenetics
Proteomics
Artificial Intelligence
Clinical Data
Multi-Omic Integration
Output
Disease-Specific Diagnostic Programs
Section 02
Four active programs across three therapeutic areas — each built on the shared Intercept IQ™ molecular substrate.
Focus. Early detection and longitudinal monitoring of autoimmune beta-cell injury associated with Type 1 Diabetes.
Applications
Primary Technologies
Focus. Detection of beta-cell dysfunction and progressive metabolic disease.
Applications
Primary Technologies
Focus. Blood-based molecular diagnostics for pancreatic cancer.
Applications
Primary Technologies
Focus. Blood-based molecular diagnostics for neurodegenerative disease.
Current Programs
Applications
Primary Technologies
Section 03
The platform architecture enables future expansion into additional disease areas without rebuilding the underlying molecular and computational infrastructure.
Intercept IQ™
Metabolic Disease
Active
Oncology
Active
Neurology
Active
Autoimmune Disease
Future Expansion
Cardiovascular Disease
Future Expansion
Transplant Medicine
Future Expansion
Rare Disease
Future Expansion
Healthy Aging
Future Expansion
Section 04
Blood-based molecular diagnostics.
Integrated biological data from multiple molecular layers.
Machine learning for multidimensional biomarker interpretation.
Monitoring biological change over time rather than relying on single-point measurements.
Section 05
A single end-to-end workflow — from patient blood draw to clinical report — that every disease program runs through.
Blood Collection
01Sample Stabilization
02Plasma Isolation
03Cell-Free DNA Extraction
04Molecular Analysis
05Quality Control
06Multi-Omic Integration
07AI Analysis
08Disease-Specific Algorithms
09Clinical Report
10Section 06
Beta Intercept™ T1D
Clinical ValidationBeta Intercept™ T2D
Clinical ValidationOnco Intercept™
Discovery & DevelopmentInitial focus: Pancreatic Cancer
Neuro Intercept AD
Research ProgramNeuro Intercept MS
Research ProgramPotential future applications:
Section 07
Section 08
Every program follows the same disciplined translational pathway — from biology to real-world clinical use.
Biological Discovery
Biomarker Identification
Analytical Validation
Clinical Validation
Regulatory Strategy
Commercial Diagnostics
Real-World Evidence
AI Platform Expansion
Section 09
Each new disease program strengthens the platform and accelerates future development — compounding scientific, clinical, and commercial value with every cycle.
Research Partnerships
Biomarker Discovery
Clinical Validation
Intellectual Property
Commercial Diagnostics
Real-World Clinical Data
Artificial Intelligence
New Disease Applications
Section 10
KiHealth is building a scalable molecular diagnostics platform designed to transform how diseases are detected, monitored, and managed. By combining liquid biopsy technologies, multi-omic biomarker discovery, artificial intelligence, and clinical research, the Intercept IQ™ platform establishes a common scientific foundation that supports multiple disease-specific diagnostic programs. As new biomarkers are discovered and validated, the platform is designed to expand into additional therapeutic areas, creating a continuously evolving ecosystem for precision diagnostics.
Pipeline Status Summary
| Program | Primary Focus | Development Stage |
|---|---|---|
| Beta Intercept™ T1D | Type 1 Diabetes | Clinical Validation |
| Beta Intercept™ T2D | Type 2 Diabetes & Metabolic Dysfunction | Clinical Validation |
| Onco Intercept™ | Pancreatic Cancer | Discovery & Development |
| Neuro Intercept AD | Alzheimer's Disease | Research Program |
| Neuro Intercept MS | Multiple Sclerosis | Research Program |
